Aptamer-Functionalized Gold Nanostars for on-Demand Delivery of Anticancer Therapeutics.

Gold nanostars (AuNS) are promising carriers for targeted delivery of therapeutic oligonucleotides, but their potential in fabricating an on-demand drug release system in a facile and robust way remains to be explored. In this paper, we used a model aptamer (HApt), acting not only as a target ligand but also as a natural thermal-responsive material, to decorate AuNS. The prepared gold nanoconstruct, HApt@AuNS, displayed stoichiometric loading capacity of the anthracycline drug doxorubicin (Dox). The on-demand drug release was realized by illuminating nanoconstructs with near-infrared (NIR) light. Furthermore, a higher degree of Dox release from the nanoconstructs was achieved in an acidic environment, compared to neutral conditions. The in vitro experiments showed that Dox-intercalation did not affect the cell uptake efficiency of HApt@AuNS, which could enter cells through clathrin-mediated endocytosis and microtubule-dependent active transport to lysosomes. Dox-loaded HApt@AuNS exhibited intracellular on-demand drug release and enhanced toxicity against cancer cells by NIR-irradiation.

TIM-3: An emerging target in the liver diseases.

T cell immunoglobulin domain and mucin domain-containing molecule 3 (TIM-3) is found expression in the surface of terminally differentiated T cells and belongs to the TIM family of type Ⅰ transmembrane proteins. It binds to the ligand Galectin-9 and mediates T cell apoptosis. As the research progresses, TIM-3 is also expressed in Th17, NK, monocyte, which binds to ligand and induce immune peripheral tolerance in both mice and man. Numerous researches have demonstrated that TIM-3 influences liver diseases, including liver-associated chronic viral infection, liver fibrosis, liver cancer et al and suggest new approaches to intervention. Currently, targeted therapy of TIM-3 is a new treatment in the field of immunization. Although many studies have proven that TIM-3 has an inhibitory effect in vivo, the specific mechanism is not clear. Herein, we summarize the important role of TIM-3 in the regulation of liver disease and prospects for future clinical research. TIM-3 will provide new targets for improving clinical liver disease.

Picroside II Protects SH-SY5Y Cells From Autophagy and Apoptosis Following Oxygen Glucose Deprivation/Reoxygen Injury by Inhibiting JNK Signal Pathway.

To explore the neuroprotective effect of picroside (Picr) II on C-Jun NH2-terminal kinase (JNK) signal pathway after oxygen glucose deprivation/reoxygen (OGD/R) in SH-SY5Y cells. In vitro, SH-SY5Y cells were used to establish the OGD/R model, which was divided into the control group, model group, Picr group, and SP600125 (SP) group. Cellular viability was measured by CCK8. Cytotoxicity was assessed with LDH assay kit. Ad-GFP-mRFP-LC3 was used to monitor autophagosome and autolysosome. Apoptoic cells were detected by Annexin V-FITC/PI apoptosis detection kit. The expressions of phospho-JNK and phospho-c-Jun were determined by western blot (WB) and immunofluorescence. The expressions of phospho-MKK4, phospho-Bcl-2, Bax, Beclin-1, and LC3 I/II were determined by WB. In the control group, only limited apoptosis and autophagy was observed, and the expression of associated proteins was very low. After OGD/R, the cellular viability of SH-SY5Y cells was reduced, whereas the cytotoxicity, apoptosis, and autophagy were increased, accompanied with an increase of phospho-MKK4, phospho-JNK, phospho-c-Jun, phospho-Bcl-2, LC3 II, Beclin-1, and Bax. During the reoxygen, treatment with Picr II or SP600125 could strengthen the cellular viability of SH-SY5Y cells, but repress the cytotoxicity, apoptosis, autophagy, and the expressions of associated protein. OGD/R could induce apoptosis and autophagy of SH-SY5Y cells by activating JNK signal pathway. Picr II could protect SH-SY5Y cells from autophagy and apoptosis following OGD/R by inhibiting JNK signal pathway. Anat Rec, 302:2245-2254, 2019. © 2019 American Association for Anatomy.